

36. The method of any one of claims 33-35, wherein the subject has a non-systemic organ-specific autoimmune disease.

37. The method of any one of claims 33-36, wherein the subject has multiple sclerosis.

38. The method of any one of claims 33-37, wherein the agent that promotes survival and/or migration of gut-derived commensal-reactive B cells is a cytokine or a chemokine.

39. The method of any one of claims 33-37, wherein the agent that promotes survival and/or migration of gut-derived commensal-reactive B cells is IL-10 and/or iNOS.

40. The method of any one of claims 33-39, wherein the gut commensal is a commensal microbe.

41. The method of any one of claims 33-40, wherein the administering an effective amount of a gut commensal comprises oral or rectal administration of a microbe or community of microbes.

42. The method of any one of claims 33-41, wherein the gut commensal comprises *Tritrichomonas musculis* or a gut microbial community that has been modified by carriage of *Tritrichomonas musculis*.

* * * * *